日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Monitoring biological effects of somatic cell genome editing

监测体细胞基因组编辑的生物学效应

Freedman, Benjamin S; Bulte, Jeff W M; Conklin, Bruce R; Judge, Luke M; Dwinell, Melinda R; Geurts, Aron M; Sitton, Madeleine J; Mahajan, Vineet; Kiani, Samira; Gersbach, Charles A; Ebrahimkhani, Mo R; Kelly, John J; Ronald, John A; Morizane, Ryuji; Gupta, Navin; Shakeri-Zadeh, Ali; Vo, Nicole; Saha, Krishanu; Saxena, Shivani; Gamm, David M; Sinha, Divya; Tarantal, Alice F; Vandsburger, Moriel; Matsubara, Azusa; Fu, Hongxia; Tsai, Shengdar Q

Longitudinal, label-free, high-resolution imaging of glioblastoma spheroid response to therapy: a translational tool for preclinical evaluation of chemotherapy, radiation, and immunotherapy

胶质母细胞瘤球体对治疗反应的纵向、无标记、高分辨率成像:一种用于化疗、放疗和免疫疗法临床前评估的转化工具

Serafini, Caroline E; Davarzani, Amin; Cappabianca, Dan; Li, Zhenmin; Baez Collazos, Daniela; Mamaghani, Deniz; Mao, Leidong; Saha, Krishanu; Karumbaiah, Lohitash; Robles, Francisco E

Class I HDAC inhibition enhances the stem-like memory properties of CRISPR-engineered CAR T cells in neuroblastoma

I类HDAC抑制剂增强了CRISPR工程化CAR T细胞在神经母细胞瘤中的干细胞样记忆特性

Cappabianca, Dan; Toulany, Mahmoud; Zima, Seth; Shea, Amanda; Vidugiriene, Jolanta; Lauer, Anthony; Sylvester, Kayla; Gnanasekar, Varun; Foster, Sean; Turaga, Rithvik; Saha, Krishanu; Ayuso, Jose; Sodji, Quaovi H

Base editing as a therapeutic strategy for somatic repeat expansion diseases

碱基编辑作为体细胞重复序列扩增疾病的治疗策略

Saha, Krishanu

Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells.

利用无病毒 CRISPR 技术将嵌合抗原受体敲入 KLRC1 中,可产生强效的 GD2 特异性自然杀伤细胞

Shankar Keerthana, Zingler-Hoslet Isabelle, Tabima Diana M, Zima Seth, Shi Lei, Gimse Kirstan, Forsberg Matthew H, Katta Varun, Davis Sage Z, Maldonado Daniel, Russell Brittany E, Murtaza Muhammed, Tsai Shengdar Q, Ayuso Jose M, Capitini Christian M, Saha Krishanu

Controlling CRISPR-Cas9 genome editing in human cells using a molecular glue degrader.

利用分子胶降解剂控制人类细胞中的 CRISPR-Cas9 基因组编辑

Khajanchi Namita, Patel Vrusha, Dua Ronak, Kabra Meha, Pattnaik Bikash R, Saha Krishanu

What does "appropriate scientific justification" mean for the review of human pluripotent stem cell, embryo, and related research?

对于人类多能干细胞、胚胎及相关研究的审查而言,“适当的科学依据”意味着什么?

Jonlin, Erica C; Fujita, Misao; Isasi, Rosario; Kato, Kazuto; Munsie, Megan; Muto, Kaori; Niakan, Kathy; Saha, Krishanu; Sugarman, Jeremy; Turner, Leigh; Hyun, Insoo

Efficient nonviral integration of large transgenes into human T cells using Cas9-CLIPT.

利用 Cas9-CLIPT 将大型转基因高效非病毒整合到人类 T 细胞中

Tommasi Anna, Cappabianca Dan, Bugel Madison, Gimse Kirstan, Lund-Peterson Karl, Shrestha Hum, Arutyunov Denis, Williams James A, Police Seshidhar Reddy, Indurthi Venkata, Davis Sage Z, Murtaza Muhammed, Capitini Christian M, Saha Krishanu

Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines.

在小鼠和猪动物模型中对视网膜下注射的 Cas9 核糖核蛋白进行评估,突显了基因药物治疗转化中的关键考虑因素

Wei Spencer C, Cantor Aaron J, Walleshauser Jack, Mepani Rina, Melton Kory, Bans Ashil, Khekare Prachi, Gupta Suhani, Wang Jonathan, Soares Craig, Kiwan Radwan, Lee Jieun, McCawley Shannon, Jani Vihasi, Leong Weng In, Shahi Pawan K, Chan Jean, Boivin Pierre, Otoupal Peter, Pattnaik Bikash R, Gamm David M, Saha Krishanu, Gowen Benjamin G, Haak-Frendscho Mary, Janatpour Mary J, Silverman Adam P

Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cells

利用抗uPAR嵌合抗原受体在T细胞产品中诱导同胞相残,从而驱动高效治疗细胞的产生

Sarko, Lauren; Givand, David; Shepley, Claire; Rattin, Brendan; Attar, Allen; Taylor, Rachel; Kutler, Benjamin; Traynor, Roshini M; Upadhyaya, Anika; Mnuk, Mackenzie; Gehrke, Cavin; Murren, Nat; Ulland, Tyler K; Kotanchek, Theresa; Saha, Krishanu